OTCM
ADAPY
Market cap2mUSD
Oct 30, Last price
0.05USD
Name
Adaptimmune Therapeutics PLC
Chart & performance
P/E
—
P/S
0.01
EPS
—
Div yield, %
—
Shrs. gr., 5y
19.17%
Rev. gr., 5y
175.49%
Revenues
178m
+195.34%
Net income
-71m
L-37.81%
CFO
-73m
L-48.04%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company dedicated to developing innovative cell therapies. Its primary focus is on addressing solid tumors in patients across the United States and the United Kingdom. At the core of its approach is the specific peptide enhanced affinity receptor (SPEAR) T-cell platform, designed to precisely identify cancer targets. The company's pipeline features several key candidates: ADP-A2M4 is in advanced clinical development, with Phase II trials underway for synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1), as well as for head and neck cancer (SPEARHEAD-2). Additionally, it is undergoing Phase I assessment for a wide range of cancers, including urothelial, melanoma, head and neck, ovarian, non-small cell lung, esophageal, gastric, synovial sarcoma, and MRCLS. ADP-A2AFP is currently in Phase I clinical trials for hepatocellular carcinoma. ADP-A2M4CD8, which utilizes SPEAR T-cells, is also in Phase I trials for treating lung, gastroesophageal, head and neck, ovarian, and bladder cancers. Adaptimmune has established a diverse portfolio of strategic collaborations, including a licensing and partnership agreement with GSK, and third-party collaborations with Noile-Immune Biotech Inc., Alpine Immune Sciences, Inc., and the National Center for Cancer Immune Therapy in Denmark. Further alliances include a strategic agreement with the MD Anderson Cancer Center and a co-development and co-commercialization agreement with Universal Cells, Inc. A significant strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd focuses on advancing personalized allogeneic T-cell therapies using aß T-cell receptors. Founded in 2008, Adaptimmune Therapeutics plc is headquartered in Abingdon, United Kingdom.
Key people
Chief Operating Officer · since 2017
John Lunger
Chief Patient Supply Officer · since 2019
Helen Katrina Tayton-Martin
Chief Business Officer · since 2017
Chief Executive Officer, Director · since 2019
Non-Executive Independent Chairman of the Board · since 2017
Non-Executive Independent Director · since 2015
Non-Executive Independent Director · since 2014
Non-Executive Independent Director · since 2016
John P. Furey
Non-Executive Independent Director · since 2018
Non-Executive Independent Director · since 2016
Legal address
60 JUBILEE AVENUE
MILTON PARK
ABINGDON, OXF OX14 4RX
GB
MILTON PARK
ABINGDON, OXF OX14 4RX
GB
Headquarters
60 JUBILEE AVENUE
MILTON PARK
ABINGDON, OXF OX14 4RY
GB
MILTON PARK
ABINGDON, OXF OX14 4RY
GB
Previous name
Adaptimmune Therapeutics Limited
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||